SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jury, E C
Right arrow Articles by Ehrenstein, M R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jury, E C
Right arrow Articles by Ehrenstein, M R
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Statins: immunomodulators for autoimmune rheumatic disease?

E C Jury

Department of Medicine, University College London, London, UK, e.jury{at}ucl.ac.uk

M R Ehrenstein

Department of Medicine, University College London, London, UK

Inhibitors of 3-hydroxy-3-methylgluttaryl coenzyme A (HMG-CoA) reductase, or statins, are used extensively to reduced elevated lipid levels and reduce cardiovascular risk. However, accumulated evidence suggests that stains not only act by lowering cholesterol levels, but also exert pleiotropic effects on many essential cellular functions including cell proliferation, differentiation, and survival and participate in the regulation of cell shape and motility. Thus cardiovascular benefit is provided by lowering raised cholesterol levels and by modulation of the inflammatory component of this disease. Such an anti-inflammatory effect may also benefit patients with autoimmune rheumatic disease. This overview assesses the evidence for using statins in patients with rheumatoid arthritis and systemic lupus erythematosus (SLE).

Key Words: rheumatoid arthritis • statins • systemic lupus erythematosus

Lupus, Vol. 14, No. 3, 192-196 (2005)
DOI: 10.1191/0961203303lu2135oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
Z Szekanecz and Y Shoenfeld
Lupus and cardiovascular disease: the facts
Lupus, November 1, 2006; 15(11_suppl): 3 - 10.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Tincani, C. B. Rebaioli, M. Taglietti, and Y. Shoenfeld
Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus
Rheumatology, October 1, 2006; 45(suppl_4): iv8 - iv13.
[Abstract] [Full Text] [PDF]


Advertisement